Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies.

SPECT dosimetry quantitation radiopharmaceutical therapy single-time-point

Journal

Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410

Informations de publication

Date de publication:
01 07 2021
Historique:
received: 05 08 2020
revised: 08 10 2020
pubmed: 1 11 2020
medline: 6 1 2022
entrez: 31 10 2020
Statut: ppublish

Résumé

Because of challenges in performing routine personalized dosimetry in radiopharmaceutical therapies, interest in single-time-point (STP) dosimetry, particularly using only a single SPECT scan, is on the rise. Meanwhile, there are questions about the reliability of STP dosimetry, with limited independent validations. In the present work, we analyzed 2 STP dosimetry methods and evaluated dose errors for several radiopharmaceuticals based on effective half-life distributions.

Identifiants

pubmed: 33127625
pii: jnumed.120.254656
doi: 10.2967/jnumed.120.254656
pmc: PMC8882881
doi:

Substances chimiques

Radiopharmaceuticals 0
copper dotatate CU-64 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1006-1011

Subventions

Organisme : CIHR
ID : MOP-142233
Pays : Canada

Informations de copyright

© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Références

Med Phys. 2019 Jun;46(6):2776-2779
pubmed: 31187571
Biomedicines. 2016 Nov 15;4(4):
pubmed: 28536392
J Nucl Med. 2018 Jan;59(1):75-81
pubmed: 28588150
Med Phys. 2018 May;45(5):2318-2324
pubmed: 29577338
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Eur J Nucl Med Mol Imaging. 2017 Aug;44(9):1490-1500
pubmed: 28361189
Phys Med Biol. 2019 Aug 28;64(17):175004
pubmed: 31456584
Med Phys. 2019 Nov;46(11):4713-4716
pubmed: 31520420
EJNMMI Phys. 2020 May 15;7(1):32
pubmed: 32415492
Molecules. 2019 Feb 11;24(3):
pubmed: 30754620
J Nucl Med. 2018 Nov;59(11):1692-1698
pubmed: 29523629
J Nucl Med. 2020 Jul;61(7):1030-1036
pubmed: 31806772
Acta Oncol. 2016 Sep - Oct;55(9-10):1069-1076
pubmed: 27219529
Phys Med Biol. 2019 Aug 28;64(17):175006
pubmed: 31287093
EJNMMI Phys. 2018 Oct 15;5(1):25
pubmed: 30318563
J Nucl Med. 2016 Jul;57(7):1006-13
pubmed: 26795286
EJNMMI Res. 2018 Apr 12;8(1):32
pubmed: 29651569
EJNMMI Phys. 2018 Dec 20;5(1):33
pubmed: 30569328
J Nucl Med. 2020 Jul;61(7):1028-1029
pubmed: 31924721

Auteurs

Xinchi Hou (X)

Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada; arman.rahmim@ubc.ca.

Julia Brosch (J)

Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.

Carlos Uribe (C)

Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.
Functional Imaging, BC Cancer, Vancouver, British Columbia, Canada.

Alessandro Desy (A)

Cancer Research Centre and Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, Quebec, Canada.
Department of Medical Imaging and Oncology, Université Laval Research Centre, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; and.

Guido Böning (G)

Department of Nuclear Medicine, University Hospital, Ludwig-Maximilians-Universität, Munich, Germany.

Jean-Mathieu Beauregard (JM)

Cancer Research Centre and Department of Radiology and Nuclear Medicine, Université Laval, Quebec City, Quebec, Canada.
Department of Medical Imaging and Oncology, Université Laval Research Centre, CHU de Québec-Université Laval, Quebec City, Quebec, Canada; and.

Anna Celler (A)

Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada.

Arman Rahmim (A)

Department of Radiology, University of British Columbia, Vancouver, British Columbia, Canada; arman.rahmim@ubc.ca.
Functional Imaging, BC Cancer, Vancouver, British Columbia, Canada.
Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH